A Review of Novel Non-Nucleoside Anti-HBV Agents and Their Mechanism of Action
Sheng Liu and Yubin Li*
College of Science, Guangdong Ocean University, Zhanjiang, 524088, P. R. China
- *Corresponding Author:
- Yubin Li
College of Science, Guangdong
Ocean University, Zhanjiang, 524088, P. R. China
E-mail: [email protected]
Received date: July 11, 2016; Accepted date: July 19, 2016; Published date: July 25, 2016
Citation: Liu S, Li Y (2016) A Review of Novel Non-Nucleoside Anti-HBV Agents and Their Mechanism of Action. Med Chem (Los Angeles) 6:521-524. doi:10.4172/2161-0444.1000393
Copyright: © 2016 Liu S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Hepatitis B virus (HBV) infection is a serious worldwide health problem as drugs (such as lamivudine and adefovir) for treating HBV are still unsatisfactory, due to high recurrence, drug resistance and inevitable side effects. Therefore, there exists a significant medical need to explore novel classes of drugs with different antiviral targets and mechanisms for anti-HBV purposes. Recently, some non-nucleoside HBV inhibitors with specific targets have been obtained from natural sources or prepared by synthesis. These compounds provide useful information for developing novel non-nucleoside compounds as anti-HBV agents.